Growth hormone holds a unique spot in the athlete's pharmacopeia. It improves body composition, accelerates recovery, enhances sleep quality, and supports connective tissue health. But GH also carries a metabolic shadow: it is a counter-regulatory hormone that directly opposes insulin's action, and chronic use can push your glucose metabolism toward insulin resistance. Left unchecked, that state carries consequences far beyond your cycle length.
The challenge is that GH-induced insulin resistance develops gradually and silently. Your liver enzymes may look perfect, your lipids may be acceptable, your blood pressure may be normal. But underneath, your cells are becoming progressively less responsive to insulin, and the markers that catch this early are not on a standard CMP.
This article covers the full picture. You'll see how GH drives insulin resistance, the dose threshold where it becomes clinically significant, and exactly what to monitor and how often. There's a tiered intervention strategy that lets you keep using GH when your markers start drifting, plus the long-term consequences you need to understand before you even begin.
How GH Causes Insulin Resistance
To understand why GH affects glucose metabolism, you first need to know what a counter-regulatory hormone is. Insulin is an anabolic hormone that tells your cells to take up glucose from the blood. GH is its physiological opposite in this context: it tells your body to preserve glucose for the tissues that need it most, namely the brain and red blood cells, by reducing glucose uptake in muscle and fat tissue.
GH drives insulin resistance through three distinct effects:
- Suppresses glucose uptake in peripheral tissues. GH reduces the expression and translocation of GLUT4 transporters in muscle and adipose tissue. Even when insulin is present and signaling properly, the cells themselves are less able to import glucose. This is the primary mechanism and the earliest to appear.
- Increases hepatic glucose production. GH stimulates gluconeogenesis in the liver: the production of new glucose from amino acids and other precursors. This increases the amount of glucose entering the bloodstream, independent of food intake.
- Promotes lipolysis. GH increases the breakdown of stored fat into free fatty acids. Elevated free fatty acids further impair insulin signaling through a phenomenon called lipotoxicity: the Randle cycle: where the availability of fatty acids reduces glucose utilization.
GH reduces glucose disposal, increases glucose production, and generates metabolic byproducts that further worsen insulin sensitivity. These three mechanisms compound each other, and the result is a progressive drift toward insulin resistance that correlates with both dose and duration of GH use.
Importantly, this isn't pathology in the traditional sense. It's the expected pharmacological effect of supraphysiological GH, and you need to hold that distinction firmly when you read your blood work. A fasting glucose of 105 mg/dL on 4 IU of GH per day is not automatically "pre-diabetes" the way it would be for someone not using GH. That's an expected pharmacological shift. But the line between "expected" and "consequential" is real, and monitoring tells you exactly where you sit on that spectrum.
The GH Dose-Response Curve
Insulin resistance from GH is dose-dependent, but the relationship is not perfectly linear. Understanding the dose thresholds helps you predict risk before you see it in the blood work.
GH Dose and Insulin Resistance Risk
| Marker | 2 IU/day | 4 IU/day |
|---|---|---|
| GLUT4 Suppression | Minimal — 10-20% reduction in glucose disposal | Moderate — 30-40% reduction |
| Hepatic Glucose Output | Mild increase (5-10%) | Moderate increase (15-25%) |
| Fasting Glucose Shift | Typically < 5 mg/dL from baseline | 5-15 mg/dL from baseline |
| Clinically Significant IR | Uncommon within 6 months | A meaningful share within 3 months |
| Intervention Typically Discussed | Rare — monitoring usually sufficient | Common — worth a conversation with a licensed medical professional |
| Recovery After Cessation | Full recovery within 2-4 weeks | Full recovery within 4-8 weeks |
4 IU/day vs. 6+ IU/day
| Marker | 4 IU/day | 6+ IU/day |
|---|---|---|
| GLUT4 Suppression | Moderate — 30-40% reduction | Significant — 50-70% reduction |
| Hepatic Glucose Output | Moderate increase (15-25%) | Large increase (30-50%) |
| Fasting Glucose Shift | 5-15 mg/dL from baseline | 15-30 mg/dL from baseline |
| Clinically Significant IR | A meaningful share within 3 months | A majority within 3 months |
| Intervention Typically Discussed | Common — worth a conversation with a licensed medical professional | Near-universal — a licensed medical professional should be closely involved |
| Recovery After Cessation | Full recovery within 4-8 weeks | May take 8-12+ weeks — not fully reversible in all users |
📈At higher GH doses, a meaningful share of users will develop clinically significant insulin resistance within a few months. Fasting insulin rises before glucose does — it is the earliest and most sensitive warning marker, and the one most often overlooked in standard blood work.
— The Core Pattern
The dose-response relationship means that 2 IU/day is genuinely low-risk from a metabolic perspective, and most users will not see meaningful insulin resistance at this dose. The jump to 4 IU/day is where monitoring becomes essential, while the jump above 4 IU/day is where intervention becomes expected, not optional. If you are using 6+ IU/day and not actively monitoring your glucose markers, you are operating without an early warning system.
The Complete Monitoring Protocol
Standard blood work panels miss the earliest signs of GH-induced insulin resistance. A CMP includes glucose, but glucose rises late in the process, after insulin resistance is already established. To catch the trend early, you need five markers, not one.
Fasting Glucose
HbA1c
Important caveat for athletes: Higher red blood cell turnover from training can falsely lower HbA1c. If your HbA1c looks suspiciously good despite elevated fasting glucose, consider fructosamine as an alternative: it captures the 2-3 week glucose average and is not affected by RBC turnover. Some athletes with excellent HbA1c values have significantly elevated fasting insulin, which HbA1c alone would miss entirely.
Fasting Insulin
HOMA-IR
Oral Glucose Tolerance Test (OGTT)
Monitoring Frequency
The optimal monitoring schedule is a balancing act between data density and practical feasibility. This protocol gives you early warning without turning your life into a clinical trial:
- Weekly: Fasting glucose (home glucometer, morning, fasted). This is your early warning system. A consistent upward trend over 2-3 weeks is actionable before any individual reading crosses a threshold.
- Every 8-12 weeks: Fasting glucose + fasting insulin + HbA1c + calculated HOMA-IR. This is your comprehensive metabolic check. Schedule it to align with your regular blood work.
- Annually (or when HbA1c rises above 5.6%): Oral Glucose Tolerance Test with insulin. This is your deep metabolic assessment, revealing insulin resistance that standard markers might miss.
The Weekly Glucometer: Your Best Investment
The Tiered Intervention Strategy
When glucose markers start drifting, you have options. The goal is not to stop GH at the first sign of insulin resistance: it is to manage the metabolic drift with targeted interventions that let you continue using GH while keeping your glucose markers in a safe range.
Intervention intensity escalates tier by tier, tracking the metabolic drift as it develops. Most users can hold at Tier 1 or Tier 2 indefinitely.
Tier 1: Diet and Lifestyle (Prevention)
Before you intervene pharmacologically, get the variables you control dialed in. A low glycemic load diet, carb timing around training (concentrating carbs in the post-training window when glycogen uptake is most efficient), and maintaining steady-state cardio all improve insulin sensitivity through independent mechanisms.
Specific recommendations: Reduce added sugars and refined carbohydrates to minimum levels. Time your carbohydrate intake primarily around training: 30-40% of daily carbs in the post-training meal. Include 20-30 minutes of steady-state cardio 4-5 times per week; even this modest amount of aerobic exercise significantly improves GLUT4 expression and glucose disposal. Maintain adequate sleep (7+ hours): sleep deprivation alone can reduce insulin sensitivity by 20-30%.
Who this is for: All GH users, regardless of dose or current markers. This is the foundation that everything else builds on. If you are using GH and not doing these things, start here regardless of your blood work.
Expected effect: Lifestyle interventions alone can offset the glucose effects of 2-3 IU/day GH in most users. At 4+ IU/day, lifestyle helps but is usually not sufficient on its own.
Tier 2: Pharmacological Support (A Licensed Medical Professional's Decision)
When lifestyle optimization isn't enough, the next step is pharmacological support — and this is exactly where it stops being a self-directed choice. Two options dominate the evidence base, and neither is something to start or dose on your own:
Berberine (commonly 500 mg twice daily with meals): Berberine improves insulin sensitivity through AMPK activation — the same pathway targeted by metformin, but through a different mechanism. It's an over-the-counter supplement, well-tolerated by most people, and often enough on its own to manage GH-induced insulin resistance at moderate doses. Give it 2-4 weeks to see the full effect on fasting glucose. Mild GI discomfort is the main side effect, usually settling within a week or two.
Metformin is a prescription medication, and starting, dosing, and titrating it is a licensed medical professional's call, not something to self-administer. It works primarily by reducing hepatic glucose production — the same pathway that GH amplifies — which is mechanistically why it's often discussed for GH users when berberine and lifestyle changes aren't enough. If your numbers point that direction, that's a conversation to have with a licensed medical professional, not a supplement aisle decision.
Berberine vs. metformin — how is this decided? As a rough guide, milder insulin resistance (fasting glucose under roughly 105 mg/dL, HOMA-IR under 2.5) is usually manageable with berberine and lifestyle changes alone. More established insulin resistance above those levels is where metformin more often becomes worth discussing with a licensed medical professional, since it's more potent and has a larger evidence base.
Tier 3: Reducing the GH Dose
If glucose markers continue to worsen despite lifestyle optimization and pharmacological support, reducing the GH dose is a reasonable and safe next step — this is not failure, it's intelligent dose management, and cutting a dose is never the risky direction. A common approach is dropping the dose by 1-2 IU/day and holding the rest of the intervention stack in place, then reassessing fasting glucose and HOMA-IR after about 4 weeks. It's still worth looping in whoever manages your protocol so the change is tracked deliberately rather than in isolation.
The general principle: GH's dose-response curve for its anabolic and recovery effects tends to be shallower than its dose-response curve for its metabolic effects, meaning a meaningful dose reduction often costs relatively little benefit while meaningfully easing the metabolic burden. Many people find that a lower dose alongside berberine or metformin preserves most of the benefit with a fraction of the metabolic drift.
Tier 4: Stopping for a Reset
If glucose markers remain elevated despite Tier 1-3 measures — persistently high fasting glucose, HbA1c, or HOMA-IR — stopping GH for a period is a safe and reasonable reset, not a last resort to fear. This is not necessarily permanent.
What a reset generally involves: stopping GH for roughly 4-8 weeks, continuing whatever pharmacological support you're on, maintaining the Tier 1 lifestyle habits, and rechecking glucose markers along the way. Most people see substantial normalization within that window. Whether and when to restart, and at what dose, is worth planning with whoever manages your protocol — restarting at a meaningfully lower dose than before, with closer monitoring, is a common and sensible approach rather than returning straight to the previous level.
Why this matters: Chronic, unmanaged insulin resistance creates long-term metabolic consequences that outlast any single GH cycle. A planned break is a reasonable price for maintaining long-term metabolic health and preserving your ability to use GH effectively for years to come.
Metformin and GH: Worth Discussing With a Licensed Medical Professional
Long-Term Consequences of Unmanaged Insulin Resistance
This section is not intended to cause alarm. It is meant to provide context for why monitoring and intervention matter beyond the current cycle. The consequences of unmanaged insulin resistance develop over years, not weeks, and they affect systems beyond glucose metabolism.
Metabolic syndrome. Insulin resistance is the core driver of metabolic syndrome — a cluster of conditions (elevated glucose, dyslipidemia, hypertension, central adiposity) that dramatically increase cardiovascular and all-cause mortality risk. GH use that pushes you into persistent insulin resistance accelerates this trajectory, especially when combined with the lipid effects of AAS. The combination of GH-driven insulin resistance and AAS-driven dyslipidemia is synergistically worse for cardiovascular risk than either alone.
Non-alcoholic fatty liver disease (NAFLD). Insulin resistance drives fat accumulation in the liver. GH users with persistent insulin resistance are at increased risk for NAFLD, which can progress to NASH (non-alcoholic steatohepatitis) over time. The liver enzymes to watch: ALT, GGT. ALT is the more specific marker for NAFLD: it rises as liver fat accumulates. If ALT trends upward over successive blood draws without a clear explanation (i.e., not from orals or training), NAFLD from insulin resistance should be on your differential. GGT helps distinguish liver fat from liver inflammation; an elevated ALT with a normal GGT is more consistent with NAFLD than with drug-induced liver injury.
Cardiovascular risk. Insulin resistance is an independent cardiovascular risk factor, separate from lipids and blood pressure. It promotes endothelial dysfunction, increases inflammation, and drives atherogenic dyslipidemia (small dense LDL, low HDL). The ApoB marker captures the atherogenic particle load more accurately than LDL alone, and insulin resistance tends to increase ApoB even when LDL looks acceptable. For GH users, combining ApoB monitoring with glucose markers gives you a more complete cardiovascular picture than either alone.
Pancreatic beta-cell exhaustion. This is the longest-term concern. Insulin resistance forces your pancreas to produce more insulin to maintain normal glucose levels. Over years, this compensatory demand can exhaust pancreatic beta cells, leading to a transition from insulin resistance to impaired glucose tolerance to frank diabetes. The annual OGTT is your best tool for assessing beta-cell reserve. A 2-hour glucose of 140-199 mg/dL (impaired glucose tolerance) is a warning sign that beta cells are struggling to keep up.
The Cumulative Effect
IGF-1 Monitoring: The Anabolic-Metabolic Balance
IGF-1 is the primary mediator of GH's anabolic effects, and monitoring it serves two purposes. First, it confirms that your GH is actually being absorbed and having an effect: if IGF-1 does not rise at all, something is off, whether that's the compound itself, the dose, or your individual response. Second, the relationship between your IGF-1 level and your glucose markers is useful context for a conversation with whoever manages your protocol about dose — not a target to dose toward on your own.
Athletes on GH commonly see a significant elevation in IGF-1 above age-adjusted norms, well below the range associated with acromegaly and its complications. Where exactly a given person's IGF-1 should sit is a question for whoever manages their protocol, weighed against age, goals, and — critically — the glucose picture, not a fixed number to self-target.
The IGF-1-to-glucose relationship: A high IGF-1 with normal glucose is a reassuring metabolic profile. A high IGF-1 alongside climbing glucose suggests the dose may be pushing past what your metabolism is comfortably handling — and that combination is exactly the kind of finding worth bringing to whoever manages your protocol to discuss dose, rather than something to resolve unilaterally.
Lab reference ranges for IGF-1 are age-stratified and often reported as Z-scores relative to your age group. Interpreting where your Z-score should sit, and what it means for your dose, is again a conversation for whoever manages your protocol — individual response varies enough between people that there's no single number that applies broadly.
Putting It All Together: Your Practical Protocol
Here's the complete protocol in actionable form, from baseline through long-term maintenance. Follow it and you'll catch metabolic drift early, intervene appropriately, and maintain the benefits of GH without accumulating long-term metabolic debt.
Before starting GH:
- Your baseline blood work should cover the full metabolic picture. That means fasting glucose, HbA1c, and fasting insulin to see how your body handles sugar over time. Add HOMA-IR to gauge insulin resistance, IGF-1 to track growth hormone activity, and a comprehensive metabolic panel to check your overall organ function and electrolyte balance.
- Your first move is establishing your lifestyle intervention, Tier 1, which means locking in a clean diet, timing your carbs around training, putting in steady-state cardio, and getting adequate sleep every night.
- Buy a home glucometer and check your fasting glucose every morning for 1-2 weeks. That gives you a personal baseline range you can actually trust before you start reading anything else into your numbers.
- If your baseline HOMA-IR is already above 2.0, or fasting glucose sits above 95 mg/dL, that's worth sorting out with a licensed medical professional before you even think about adding GH.
During GH use:
- For fasting glucose, check it weekly with a home glucometer. Pick one morning per week, same day each week, and make sure you're fasted when you test.
- At week 4, check fasting glucose and insulin, then calculate HOMA-IR from those values to assess early metabolic drift.
- At week 12, run a full metabolic panel. That includes fasting glucose, HbA1c, fasting insulin, HOMA-IR, and IGF-1.
- A HOMA-IR creeping past 2.5, or fasting glucose holding above 100 mg/dL, is your cue to add pharmacological support — berberine is a reasonable first step on your own, while metformin needs a licensed medical professional.
- If markers continue to worsen despite that support, reducing the GH dose by 1-2 IU/day is a safe next move, and worth doing alongside whoever manages your protocol.
- If markers are still elevated after a dose reduction, a temporary break from GH — commonly 4-8 weeks — is the next step, planned with whoever manages your protocol.
Annual deep assessment:
- The Oral Glucose Tolerance Test with insulin assesses beta-cell reserve and reveals insulin resistance that standard markers miss.
- A full metabolic panel including ApoB is the way to go. Insulin resistance and ApoB are synergistic cardiovascular risk factors, and you should track them together.
- If your ALT has been trending upward, a liver ultrasound directly assesses NAFLD progression.
Between cycles:
- Taking real time off between GH cycles matters more than most people think, because growth hormone's effects on your body don't just switch off the day you stop — how long to leave, and when to restart, is worth planning with whoever manages your protocol rather than a fixed number of weeks.
- A few weeks in, pulling fasting glucose and insulin helps confirm recovery is on track.
- If your markers haven't fully normalized by the time you'd planned to restart, that's worth extending the break and discussing other possible metabolic stressors with a licensed medical professional, rather than rushing back in on schedule.
- A HOMA-IR above 2.0 or fasting glucose above 100 mg/dL heading into a new cycle is worth resolving first — starting GH on top of unresolved insulin resistance means fighting it from day one, and that's a conversation to have with whoever manages your protocol before you add that variable back.